Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients

AstraZeneca914 enrolled

Overview

This open label, non-interventional study is to show the efficacy of Pulmicort®Respules® in cough variant asthma in patient aged 5-year old or younger in outpatient department

Study Type

OBSERVATIONAL

Enrollment

914

Conditions

Cough Variant Asthma

Eligibility

Sex: ALLMax age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of informed consent * Patient who has been prescribed Pulmicort® Respules® according to physician's judgement, irrespective of the inclusion in the study. * The usage of Pulmicort® Respules® follows local authorised package insert. Exclusion Criteria: * Allergy to any ingredient of Pulmicort® Respules® * With history of Leukotriene Modifier (LM) usage prior to 2 weeks of recruitment or following plan. * Have used systemic/inhaled steroid prior to 2 weeks of recruitment

Locations (32)

Research Site

Hefei, Anhui, China

Outcomes

Primary Outcomes

Patient Symptom Score

Time frame: 7 weeks (plus or minus 3 days )

Secondary Outcomes

Patient Compliance Report

Time frame: 7 weeks (plus or minus 3 days )

Investigator Assessment Report

Time frame: 7 weeks (plus or minus 3 days )

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.